Kornitzer Capital Management Inc. KS Acquires 1,031 Shares of AstraZeneca PLC (NASDAQ:AZN)

Kornitzer Capital Management Inc. KS boosted its holdings in AstraZeneca PLC (NASDAQ:AZN) by 0.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 360,312 shares of the company’s stock after acquiring an additional 1,031 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in AstraZeneca were worth $28,072,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. McClarren Financial Advisors Inc. lifted its stake in shares of AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares during the last quarter. GHP Investment Advisors Inc. bought a new position in AstraZeneca in the 2nd quarter valued at about $26,000. Pathway Financial Advisers LLC acquired a new stake in AstraZeneca during the first quarter worth approximately $29,000. RFP Financial Group LLC boosted its holdings in shares of AstraZeneca by 56.3% during the first quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock worth $33,000 after acquiring an additional 178 shares during the period. Finally, CANADA LIFE ASSURANCE Co grew its position in shares of AstraZeneca by 40.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after purchasing an additional 146 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Down 0.1 %

Shares of AZN traded down $0.04 during trading hours on Thursday, hitting $63.81. The company had a trading volume of 3,210,361 shares, compared to its average volume of 5,117,211. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The stock has a market capitalization of $197.85 billion, a price-to-earnings ratio of 30.85, a P/E/G ratio of 1.32 and a beta of 0.47. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The firm has a fifty day moving average price of $78.45 and a 200-day moving average price of $78.75.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. TD Cowen lifted their price target on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.